Drug Topics - October 22, 2007 - (Page 38)

38 DRUG TOPICS OCTOBER 22, 2007 www.drugtopics.com > > > New Products Rx NEW DRUGS CSL Biotherapies, King of Prussia, Pa., has received FDA approval for a chicken-egg-based single-dose seasonal influenza vaccine. Afluria is indicated as a protection against the flu in people age 18 years and older. For further information, CSL can be reached at (888) 4FLU-OFF. A new drug for the treatment of hypertension has been approved for Daiichi Sankyo, Parsippany, N.J., (973) 359-2600. Azor (amlodipine and olmesartan medoxomil), a single tablet, combines a calciumchannel blocker and an angiotensin receptor blocker. It is not indicated for the initial therapy of hypertension. NEW INDICATIONS Evista (raloxifene hydrochloride), the selective estrogen receptor blocker from Eli Lilly & Co., Indianapolis, (317) 277-6583, has been approved for a new indication. It can now be used to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer. Ortho-McNeil Pharmaceutical, Raritan, N.J., (800) 682-6532, has approval for two new indications for the broad-spectrum antibiotic Levaquin (levofloxacin). One approval covers the use of a 750-mg daily dosage of Levaquin IV, Levaquin Oral Tablets, and Levaquin Oral Solution for five days for the treatment of complicated urinary tract infection and acute pyelonephritis. The other provides for the addition of pediatric safety information for the Oral Tablet, the IV, and the Oral Solution. ADVERTISERS INDEX ACCU-CHEK (Roche Diagnostics) . . . . . . . . . . . . . . . . . . . IFC CEFOTETAN (Abraxis Pharmaceutical Partners) . . . . HSE5 CORPORATE (Customer Link) . . . . . . . . . . . . . . . . . . . . HSE9 CORPORATE (Emporos Systems) . . . . . . . . . . . . . . . . . HSE8 CORPORATE (Lexi-Comp) . . . . . . . . . . . . . . . . . . . . . . HSE2-3 CORPORATE (Mylan Laboratories) . . . . . . . . . . . . . . . . . . . . 3 CORPORATE (Target) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 CORPORATE (University of Pittsburgh) . . . . . . . . . . . . . . . 39 DORIPENEM (Ortho-McNeil) . . . . . . . . . . . . . . . . . . . HSE24 FLEX PEN (Novo Nordisk) . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 FREESTYLE (Abbott Laboratories) . . . . . . . . . . . . . . . . . . . . 11 INVEGA (Janssen Pharmaceutica) . . . . . . . . . . . . HSE16-19 IPRATROPIUM/ALBUTEROL (Sandoz Inc.) . . . . . . . . . . . 5 LEVEMIR (Novo Nordisk) . . . . . . . . . . . . . . . . . . . . . . IBC-BC LEXAPRO (Forest Laboratories) . . . . . . . . . . . . . INSERT, 13 NEBIVOLOL (Forest Laboratories) . . . . . . . . . . . . . . INSERT RX ESSENTIALS (Pharmavite) . . . . . . . . . . . . . . . . . . . . . . 15 TAMPALERT (EPS Inc.) . . . . . . . . . . . . . . . . . . . . . . . . . . HSE7 TEACHING AID (Innovia Medical) . . . . . . . . . . . . . . . . 23-24 THROMBIN (King Pharmaceuticals) . . . . . . . . . . HSE12-14 TYGACIL (Wyeth Pharmaceuticals) . . . . . . . . . . . HSE21-22 ULTRAMINI (LifeScan Inc.) . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 IFC-Inside front cover IBC-Inside back cover BC-Back cover NEW DOSAGE STRENGTHS MedPointe Pharmaceuticals, Somerset, N.J., (800) 526-3840, has FDA approval for a 250-mg tablet for SOMA (carisoprodol) for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. The recommended dose is 250 mg three times a day and at bedtime. SOMA 250 mg offers relief comparable to that provided by already available SOMA 350 mg but with less drowsiness. Sanofi-aventis, Bridgewater, N.J., (908) 243-6000, and Bristol-Myers Squibb, Princeton, N.J., (609) 2524000, have received approval for a 300-mg tablet of the antiplatelet medication Plavix (clopidogrel bisulfate). This new strength will provide the approved loading dose for acute coronary syndrome. NOW AVAILABLE Xyzal (levocetirizine dihydrochloride) is now available from UCB Pharma, Atlanta, (800) 477-7877, and Sanofi-aventis, Bridgewater, N.J., (908) 243-6000. The once-daily medication is indicated for treating indoor and outdoor allergies as well as chronic idiopathic urticaria. It is approved for use in adults and children six years of age and older. NEW GENERICS From Teva Pharmaceuticals, North Wales, Pa., (888) http://www.drugtopics.com

Table of Contents Feed for the Digital Edition of Drug Topics - October 22, 2007

Drug Topics - October 22, 2007 Contents Latebreakers Legislative Victory Builds Momentum for Pharmacy Month Letters Health-System Edition R.Ph.s Brace for Payment Denial for Hospital-Acquired Conditions Topical Human Thrombin Helps Arrest Bleeding FDA Panels Fail to Set Target Levels for Renal Patients’ Hemoglobin Warning Letters Raise Patient Safety Concerns for Fentora Ending/Reversing Weight Gain Man Given Fatal Drug Overdose at Staten Island Hospital Pharmacists Playing More Important Role in Dialysis Treatment AHA President R.Ph.'s Here's How You Can Increase Your Value Premier Launches Comprehensive Quality Improvement Project FDA Approves Dexrazoxane for Treatment of Extravasation New Federal, State Reforms to Ease Disaster Relief Kinks 150 Years of American Pharmacy Ten Tips for MTM Success Independent Superstars: The Ones to Watch The New Dynamic Duo A Parkinson's Disease Primer Classified New Products Advertisers Index Viewpoint

Drug Topics - October 22, 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.